Brain Frontier dedicated to the discovery and development of innovative small molecule medicines by harnessing the power of immune checkpoint proteins. Our team is

comprised of seasoned drug developers with deep knowledge and expertise in PD-1 related drug discovery.

PD-1 has been implicated in CNS disorders such as brain tumors, Alzheimer’s disease, ischemic stroke, spinal cord injury, multiple sclerosis, cognitive function, and pain. Using a proprietary PD-1 related drug discovery platform and robust screening capabilities, we are advancing a diverse pipeline of highly selective small-molecule candidates across multiple therapeutic areas.

Our mission is to develop powerful therapies to treat human brain diseases and improve the quality of life of patients. The company, headquartered in southern California, has research operations in both the United States and China.